MX2025005591A - Cristal de derivado de piperazina sustituido y metodo de preparacion del mismo - Google Patents

Cristal de derivado de piperazina sustituido y metodo de preparacion del mismo

Info

Publication number
MX2025005591A
MX2025005591A MX2025005591A MX2025005591A MX2025005591A MX 2025005591 A MX2025005591 A MX 2025005591A MX 2025005591 A MX2025005591 A MX 2025005591A MX 2025005591 A MX2025005591 A MX 2025005591A MX 2025005591 A MX2025005591 A MX 2025005591A
Authority
MX
Mexico
Prior art keywords
preparation
crystal
method therefor
piperazine derivative
substituted piperazine
Prior art date
Application number
MX2025005591A
Other languages
English (en)
Spanish (es)
Inventor
Zhaojun Liu
Hongzhu Chu
Yuqin Zhu
Xin Cao
Yonggang Wei
Yi Sun
Original Assignee
Kangbaida Sichuan Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kangbaida Sichuan Biotechnology Co Ltd filed Critical Kangbaida Sichuan Biotechnology Co Ltd
Publication of MX2025005591A publication Critical patent/MX2025005591A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MX2025005591A 2022-11-14 2025-05-13 Cristal de derivado de piperazina sustituido y metodo de preparacion del mismo MX2025005591A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211417721 2022-11-14
PCT/CN2023/131627 WO2024104354A1 (zh) 2022-11-14 2023-11-14 一种取代的哌嗪衍生物的晶体及其制备方法

Publications (1)

Publication Number Publication Date
MX2025005591A true MX2025005591A (es) 2025-06-02

Family

ID=90997576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025005591A MX2025005591A (es) 2022-11-14 2025-05-13 Cristal de derivado de piperazina sustituido y metodo de preparacion del mismo

Country Status (9)

Country Link
US (1) US20250270223A1 (https=)
EP (1) EP4620958A1 (https=)
JP (1) JP2025536416A (https=)
KR (1) KR20250086779A (https=)
CN (1) CN118027039A (https=)
AU (1) AU2023381502A1 (https=)
MX (1) MX2025005591A (https=)
TW (1) TWI879228B (https=)
WO (1) WO2024104354A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202508597A (zh) * 2023-08-17 2025-03-01 大陸商康百達（四川）生物醫藥科技有限公司 一種呱嗪衍生物的藥物製劑、其製備方法及其用途
WO2025209574A1 (zh) * 2024-04-03 2025-10-09 康百达（四川）生物医药科技有限公司 用于预防或治疗肿瘤的parp7抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3788040T3 (fi) * 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
CN112745312B (zh) * 2019-10-30 2022-08-30 沈阳中化农药化工研发有限公司 哒嗪酮异恶唑甲醚类化合物及其应用
US20240190844A1 (en) * 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
CN116157396B (zh) * 2020-11-27 2025-07-18 康百达（四川）生物医药科技有限公司 哒嗪酮衍生物及其在医药上的应用
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
KR20240012534A (ko) * 2021-05-21 2024-01-29 청두 바이위 파머수티컬 씨오., 엘티디 피페라진 유도체 및 이의 의학적 용도

Also Published As

Publication number Publication date
CN118027039A (zh) 2024-05-14
TW202426452A (zh) 2024-07-01
WO2024104354A1 (zh) 2024-05-23
TWI879228B (zh) 2025-04-01
AU2023381502A1 (en) 2025-05-15
EP4620958A1 (en) 2025-09-24
US20250270223A1 (en) 2025-08-28
JP2025536416A (ja) 2025-11-05
KR20250086779A (ko) 2025-06-13

Similar Documents

Publication Publication Date Title
MX2025005591A (es) Cristal de derivado de piperazina sustituido y metodo de preparacion del mismo
PH12022552395A1 (en) Pyrimidoheterocyclic compounds and application thereof
ZA202500635B (en) Piperazine bridge-substituted heterocyclic pyrimidine compound
ZA202406389B (en) Benzopyrimidine compounds and use thereof
MX2025003665A (es) Derivados macrociclicos y las aplicaciones de estos
MX2023009278A (es) Compuestos ciclicos aromaticos pirimidina.
ZA202403530B (en) Method for preparing l-glufosinate
MX2024015714A (es) Compuesto de pirimidopirano sustituido heterocíclico y uso de este
ZA202104112B (en) 15-pgdh inhibitor
WO2022251561A3 (en) Spiroindolinone compounds as kv1.3 potassium shaker channel blockers
MX2025006444A (es) Proceso para la sintesis de moduladores de tetrahidrofurano sustituidos de los canales de sodio
MX2023000970A (es) Metodo de preparacion de aminofuranos.
EP4410989A3 (en) Method for producing heterocyclidene acetamide derivatives
ZA202301378B (en) Solid form of compound
ZA202402459B (en) Compounds for regulating trained immunity, and their methods of use
WO2023150592A3 (en) N3-substituted uracil compounds as trpa1 inhibitors
WO2022057836A8 (zh) 苯并脲环衍生物及其制备方法和应用
PH12021552787A1 (en) Tetracyclic compounds as cdc7 inhibitors
PH12021552225A1 (en) Crystal of heterocyclic amide compound and method for producing same
EP4538275A8 (en) Crystal of dihydropyridinone derivative or solvate thereof
MX2023012804A (es) Forma cristalina de derivado de tiofeno y metodo de preparacion de la misma.
WO2023150591A3 (en) Pyridazinone compounds as trpa1 inhibitors
PH12023552751A1 (en) ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS.
MX2025009371A (es) Forma cristalina de derivado de sulfonamida y metodo de preparacion para ello
MX2021014246A (es) Procedimientos y productos intermedios para preparar un inhibidor de btk.